RPRX

Royalty Pharma plc

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$68.97

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %42.8 / %30

Non-compliant assets / Total market cap %88.3 / %30

Non-compliant revenue / Total income %0.8 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.

Website

Analysis (Turkish): RPRX Hissesi Caiz mi, Helal mi? Royalty Pharma plc Katılım Analizi